{"id":"cell-therapy-with-bispecific-antibodies","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune activation-related toxicity"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL4298070","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This cell therapy approach uses engineered bispecific antibodies that bridge cancer cells and T cells or other immune effectors, bringing them into close proximity to trigger cytotoxic killing. By targeting two distinct antigens—one on the tumor and one on the immune cell—the bispecific antibodies create a dual-recognition system that enhances specificity and immune activation against malignant cells.","oneSentence":"Bispecific antibodies redirect immune cells to recognize and eliminate cancer cells by simultaneously binding to tumor-associated antigens and immune cell receptors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:50:28.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (phase 2 investigational)"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT07151690","phase":"PHASE2","title":"BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-04","conditions":"Systemic Light Chain Amyloidosis","enrollment":21},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT07258511","phase":"PHASE3","title":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-02-04","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT06892548","phase":"PHASE1, PHASE2","title":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-05-02","conditions":"Advanced Lung Cancer","enrollment":594},{"nctId":"NCT05828511","phase":"PHASE1, PHASE2","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-19","conditions":"Multiple Myeloma","enrollment":149},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT04634552","phase":"PHASE2","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hematological Malignancies","enrollment":510},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT06712316","phase":"PHASE2, PHASE3","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-01-07","conditions":"Non-small Cell Lung Cancer","enrollment":1260},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT07393282","phase":"PHASE3","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-25","conditions":"High Risk Smoldering Multiple Myeloma (HR-SMM)","enrollment":270},{"nctId":"NCT06150157","phase":"PHASE1","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Neoplasms","enrollment":220},{"nctId":"NCT06841055","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-03-03","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04108195","phase":"PHASE1","title":"A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-21","conditions":"Multiple Myeloma","enrollment":290},{"nctId":"NCT06510491","phase":"PHASE2","title":"Epcoritamab in Previously Treated WM","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2024-12-06","conditions":"Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder","enrollment":20},{"nctId":"NCT06442475","phase":"PHASE2","title":"Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-08-29","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":20},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06479239","phase":"PHASE1, PHASE2","title":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-11-06","conditions":"Pancreas Cancer, Pancreatic Cancer","enrollment":23},{"nctId":"NCT07133997","phase":"PHASE1","title":"Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":26},{"nctId":"NCT05338775","phase":"PHASE1","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-25","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":74},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT07460362","phase":"PHASE2","title":"Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-08-11","conditions":"MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":43},{"nctId":"NCT06890494","phase":"EARLY_PHASE1","title":"Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-01-18","conditions":"Leukemia","enrollment":3},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT07010263","phase":"PHASE3","title":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-13","conditions":"Small Cell Lung Cancer","enrollment":560},{"nctId":"NCT05247684","phase":"PHASE2","title":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-02-20","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT07452003","phase":"NA","title":"An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-03","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT07448116","phase":"PHASE1, PHASE2","title":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2026-01-31","conditions":"Solid Advanced Tumor","enrollment":164},{"nctId":"NCT07029776","phase":"PHASE2","title":"MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-07-01","conditions":"Multiple Myeloma (MM)","enrollment":50},{"nctId":"NCT05660967","phase":"PHASE2","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-03-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":111},{"nctId":"NCT06806033","phase":"PHASE2","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-05","conditions":"B-Cell Non-Hodgkins Lymphoma","enrollment":100},{"nctId":"NCT06817889","phase":"PHASE2","title":"Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-23","conditions":"Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection","enrollment":60},{"nctId":"NCT07049055","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":"Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":144},{"nctId":"NCT03272334","phase":"PHASE1, PHASE2","title":"Her2-BATS and Pembrolizumab in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2017-12-29","conditions":"Metastatic Breast Cancer","enrollment":22},{"nctId":"NCT03263572","phase":"PHASE2","title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-29","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression","enrollment":90},{"nctId":"NCT07432022","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2026-03-01","conditions":"Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07","enrollment":115},{"nctId":"NCT06811272","phase":"PHASE2","title":"Outpatient Epcoritamab as 2L in NTE R/R DLBCL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-06-05","conditions":"Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT05090566","phase":"PHASE2","title":"MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-10-27","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT06546553","phase":"PHASE1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-09-06","conditions":"Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT07423585","phase":"PHASE2","title":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Asrar Alahmadi","startDate":"2026-04-01","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":39},{"nctId":"NCT06536049","phase":"PHASE1, PHASE2","title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Yazeed Sawalha","startDate":"2025-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":38},{"nctId":"NCT07420959","phase":"PHASE1, PHASE2","title":"ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-25","conditions":"Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia","enrollment":38},{"nctId":"NCT05861050","phase":"PHASE1, PHASE2","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-10","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT06723457","phase":"PHASE2","title":"Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2025-07-25","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT07293754","phase":"PHASE1, PHASE2","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Repertoire Immune Medicines","startDate":"2025-12-12","conditions":"Advanced Malignant Solid Tumor","enrollment":150},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT05014412","phase":"PHASE2","title":"A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-07","conditions":"Multiple Myeloma","enrollment":86},{"nctId":"NCT07105059","phase":"PHASE1","title":"A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT05535244","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-17","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT07393555","phase":"PHASE2","title":"Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-08-07","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT06565689","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012","status":"RECRUITING","sponsor":"Excyte Biopharma Ltd","startDate":"2023-05-09","conditions":"Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":48},{"nctId":"NCT05633615","phase":"PHASE2","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-06-12","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":396},{"nctId":"NCT02651662","phase":"PHASE1","title":"A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-11","conditions":"Relapsed/Refractory Aggressive B-Cell Lymphoma","enrollment":105},{"nctId":"NCT06357676","phase":"PHASE1, PHASE2","title":"Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-05-29","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07009899","phase":"PHASE2","title":"BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Multiple Myeloma","enrollment":34},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma","enrollment":43},{"nctId":"NCT07363408","phase":"PHASE1","title":"Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-21","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":30},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751},{"nctId":"NCT04586426","phase":"PHASE1, PHASE2","title":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-15","conditions":"Multiple Myeloma","enrollment":228},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":"B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":18},{"nctId":"NCT05544968","phase":"PHASE1","title":"Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma","enrollment":42},{"nctId":"NCT07159828","phase":"PHASE1","title":"A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Axion Bio, Inc","startDate":"2025-09-15","conditions":"Solid Tumor, Adult","enrollment":52},{"nctId":"NCT05464329","phase":"PHASE1","title":"Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-03","conditions":"Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma","enrollment":24},{"nctId":"NCT06043674","phase":"PHASE2","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2024-01-22","conditions":"Chronic Lymphocytic Leukemia, Richter's Transformation","enrollment":70},{"nctId":"NCT07093554","phase":"PHASE1","title":"Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-02","conditions":"Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":31},{"nctId":"NCT06054776","phase":"PHASE2","title":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-02","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT07266116","phase":"PHASE1, PHASE2","title":"Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-26","conditions":"Systemic Light Chain Amyloidosis","enrollment":70},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07171606","phase":"PHASE2","title":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-10-24","conditions":"First-line Advanced NSCLC Patients","enrollment":240},{"nctId":"NCT07286942","phase":"PHASE2","title":"Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-12-18","conditions":"NSCLC, NSCLC (Non-small Cell Lung Cancer)","enrollment":24},{"nctId":"NCT05410418","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-10-24","conditions":"Lymphoma, Follicular, Follicular Lymphoma","enrollment":34},{"nctId":"NCT06251076","phase":"PHASE4","title":"Plan Development for Giving Teclistamab in the Outpatient Setting","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-11-19","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Cancer","enrollment":15},{"nctId":"NCT06116682","phase":"PHASE2","title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-19","conditions":"Lung Non-Small Cell Carcinoma","enrollment":88},{"nctId":"NCT07014319","phase":"PHASE2","title":"Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-11-03","conditions":"Cytomegalovirus (CMV)","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2035,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cell therapy with bispecific antibodies","genericName":"Cell therapy with bispecific antibodies","companyName":"Hadassah Medical Organization","companyId":"hadassah-medical-organization","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bispecific antibodies redirect immune cells to recognize and eliminate cancer cells by simultaneously binding to tumor-associated antigens and immune cell receptors. Used for Hematologic malignancies (phase 2 investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}